[1]陈淑平,徐 铭,刘元东.替戈拉生联合高剂量阿莫西林二联方案根除治疗幽门螺杆菌的疗效观察[J].医学信息,2025,38(23):97-100.[doi:10.3969/j.issn.1006-1959.2025.23.019]
　CHEN Shuping,XU Ming,LIU Yuandong.Observation on the Efficacy of Tegoprazan and High-dose AmoxicillinDual Therapy for Eradicating Helicobacter Pylori[J].Journal of Medical Information,2025,38(23):97-100.[doi:10.3969/j.issn.1006-1959.2025.23.019]
点击复制

替戈拉生联合高剂量阿莫西林二联方案根除治疗幽门螺杆菌的疗效观察()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年23期
页码:
97-100
栏目:
论著
出版日期:
2025-12-01

文章信息/Info

Title:
Observation on the Efficacy of Tegoprazan and High-dose AmoxicillinDual Therapy for Eradicating Helicobacter Pylori
文章编号:
1006-1959（2025）23-0097-04
作者:
陈淑平; 徐 铭; 刘元东
上饶市广信区人民医院消化内科，江西 上饶 334100
Author(s):
CHEN Shuping;  XU Ming;  LIU Yuandong
Department of Gastroenterology, Shangrao Guangxin District People′s Hospital, Shangrao 334100, Jiangxi, China
关键词:
幽门螺杆菌; 替戈拉生; 阿莫西林
Keywords:
Helicobacter pylori;  Tegoprazan;  Amoxicillin
分类号:
R573.6
DOI:
10.3969/j.issn.1006-1959.2025.23.019
文献标志码:
A
摘要:
目的 探究替戈拉生（TPZ）联合高剂量阿莫西林（AMO）二联方案根除治疗幽门螺杆菌（Hp）的临床效果。方法 选取2024年6月-12月上饶市广信区人民医院拟行Hp根除治疗的300例Hp感染患者，经随机数字表法分为观察组（n=142）与对照组（n=158）。观察组应用TPZ+高剂量AMO二联疗法，对照组应用含铋剂四联疗法，比较两组Hp根除率、症状积分、临床疗效与不良反应。结果 观察组与对照组Hp根除率比较（ITT分析：85.92% vs. 84.81%；PP分析：88.03% vs. 87.34%），差异无统计学意义（P＞0.05）；两组治疗后症状积分（腹痛、腹胀、嗳气）均低于治疗前（P＜0.05），但组间比较，差异无统计学意义（P＞0.05）；观察组与对照组治疗有效率比较（91.55% vs. 91.14%），差异无统计学意义（P＞0.05）；观察组不良反应发生率低于对照组（7.75% vs. 15.82%），差异有统计学意义（P＜0.05）。结论 TPZ联合高剂量AMO二联方案可有效改善Hp感染患者的临床症状，其Hp根除率、综合疗效与常规四联疗法相当，且表现出良好的用药安全性。
Abstract:
Objective To explore the clinical effect of tegoprazan (TPZ) combined with high-dose amoxicillin (AMO) dual therapy in the eradication of Helicobacter pylori (Hp). Methods From June to December 2024, 300 patients with Hp infection who were scheduled to undergo Hp eradication in Shangrao Guangxin District People’s Hospital were selected and divided into observation group (n=142) and control group (n=158) by random number table method. The observation group was treated with TPZ+high-dose AMO dual therapy, and the control group was treated with bismuth-containing quadruple therapy. The Hp eradication rate, symptom score, clinical efficacy and adverse reactions were compared between the two groups. Results There was no significant difference in Hp eradication rate between the observation group and the control group (ITT analysis: 85.92% vs. 84.81%; PP analysis: 88.03% vs. 87.34%) (P>0.05). The symptom scores (abdominal pain, abdominal distension, belching) of the two groups after treatment were lower than those before treatment (P<0.05), but there were no significant difference between the two groups (P>0.05). There was no significant difference in the effective rate between the observation group and the control group (91.55% vs. 91.14%) (P>0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (7.75% vs. 15.82%), the difference was statistically significant (P<0.05). Conclusion TPZ combined with high-dose AMO dual therapy can effectively improve the clinical symptoms of patients with Hp infection， its Hp eradication rate and comprehensive efficacy are comparable to those of conventional quadruple therapy, and it shows good drug safety.

参考文献/References:

[1]刘宏明,王敏,孟雅洁,等.伏诺拉生联合阿莫西林、克拉霉素的三联方案根除幽门螺杆菌的效果评价研究[J].中国医院用药评价与分析,2025,25(2):157-160.[2]杜君彦,潘杰,周晴接,等.2013-2020年浙江温州地区幽门螺杆菌耐药情况分析[J].中国全科医学,2023,26(7):825-829.[3]张新星,黄微,李良平,等.含铋剂不同四联方案对幽门螺杆菌初治患者的疗效及安全性研究[J].华西药学杂志,2022,37(6):698-700.[4]杨小红,杨海涛,刘超,等.含阿莫西林克拉维酸钾的铋剂四联方案治疗幽门螺杆菌感染致慢性胃炎的有效性及安全性观察[J].药物评价研究,2022,45(9):1863-1869.[5]黄琳琅,黄笑芳,刘艳艳,等.钾离子竞争性酸阻滞剂的临床综合评价[J].中国药房,2024,35(23):2851-2857.[6]赵文涛,孙涵,焦小红.替戈拉生联合伊托必利治疗反流性食管炎患者的效果及安全性[J].中国药物应用与监测,2025,22(1):34-37.[7]刘涛,董赛书,毛孝周,等.伏诺拉生联合阿莫西林根除幽门螺杆菌的疗效分析[J].临床药物治疗杂志,2024,22(6):56-60.[8]王世令,陈丹妮,刘兆,等.伏诺拉生二联方案根除幽门螺杆菌的疗效观察[J].现代消化及介入诊疗,2024,29(3):265-269.[9]中华医学会消化病学分会幽门螺杆菌学组.2022中国幽门螺杆菌感染治疗指南[J].胃肠病学,2022,27(3):150-162.[10]卢晓平,丁左缨.2013-2020年海安地区幽门螺杆菌感染病例特征及耐药性变化趋势[J].华南预防医学,2022,48(3):330-332,336.[11]刘国华,周娴,叶彬明,等.伏诺拉生联合高剂量阿莫西林二联方案根除幽门螺杆菌的疗效[J].新医学,2024,55(3):204-207.[12]黄元龙,左后东,毛本红,等.伏诺拉生与阿莫西林二联方案根除幽门螺杆菌的真实世界研究[J].中国药房,2023,34(22):2775-2779.[13]郑旭林,陈拥军,余欣鑫,等.大剂量阿莫西林联合艾司奥美拉唑二联方案治疗幽门螺杆菌感染的疗效及安全性[J].华西医学,2023,38(4):513-517.[14]毕含鑫.高剂量艾司奥美拉唑和阿莫西林双联疗法补救治疗根除幽门螺杆菌的有效性及安全性研究[D].西安:西安医学院,2022.[15]王婷,柴春艳,李敏.伏诺拉生联合阿莫西林二联疗法根除老年患者幽门螺杆菌感染的疗效[J].胃肠病学和肝病学杂志,2023,32(8):872-874.[16]王先令,闭彩莹,李思琼,等.伏诺拉生联合高剂量阿莫西林新二联七天方案治疗幽门螺杆菌感染的应用价值分析[J].西部医学,2024,36(12):1854-1858.[17]刘晓菲,王静,樊贞瑜,等.富马酸伏诺拉生替代PPI治愈难治性幽门螺杆菌感染[J].胃肠病学和肝病学杂志,2022,31(9):990-991.[18]杨桂彬.伏诺拉生和低剂量阿莫西林组成的二联7 d方案是潜在新的一线幽门螺杆菌治疗方案[J].中华医学杂志,2020,100(30):2382.[19]邵俏俏,马菁,余雪纯,等.雷贝拉唑联合阿莫西林或呋喃唑酮二联疗法根除幽门螺杆菌感染的临床疗效研究[J].中国全科医学,2022,25(29):3640-3645.[20]齐涛,钱丹烨,朱黎明.不同抗生素组合的含铋剂四联方案根除幽门螺杆菌的疗效分析[J].国际消化病杂志,2022,42(3):200-203.[21]赵京平,王誉敏,游云龙,等.艾司奥美拉唑联合阿莫西林方案与含铋剂四联方案对幽门螺杆菌感染初治患者的疗效比较[J].实用临床医药杂志,2022,26(12):51-55,60.[22]朱健伟,徐鹏,王佳艳,等.雷贝拉唑联合阿莫西林高剂量二联疗法与铋剂四联疗法根除幽门螺杆菌感染有效性和安全性的比较研究[J].胃肠病学,2022,27(1):17-20.[23]张晚晴,孙大勇,胡晶晶,等.双倍剂量质子泵抑制剂联合阿莫西林疗法补救治疗幽门螺杆菌感染的疗效及安全性分析[J].现代消化及介入诊疗,2022,27(4):493-497.[24]朱志超,郭雅丽,张健,等.伏诺拉生联合阿莫西林治疗幽门螺杆菌感染首次治疗患者的临床疗效及安全性研究[J].传染病信息,2024,37(6):546-549.[25]邱红,陈宇桥,陈万群,等.改良二联方案治疗幽门螺杆菌感染的疗效观察[J].重庆医学,2022,51(3):414-417.

相似文献/References:

[1]郭绍敏.克拉霉素四联方案对一线方案根除失败的幽门螺杆菌的再根除效果评估[J].医学信息,2018,31(02):121.[doi:10.3969/j.issn.1006-1959.2018.02.044]
　GUO Shao-min.Evaluation of the Re-eradication Effect of Clarithromycin Quadruple Regimen on Helicobacter Pylori Eradication Failure in the First Line Scheme[J].Journal of Medical Information,2018,31(23):121.[doi:10.3969/j.issn.1006-1959.2018.02.044]
[2]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Journal of Medical Information,2018,31(23):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[3]马艳会,寇 毅.幽门螺杆菌感染与结直肠腺瘤临床特征的相关性研究[J].医学信息,2022,35(16):102.[doi:10.3969/j.issn.1006-1959.2022.16.024]
　MA Yan-hui,KOU Yi.Correlation Between Helicobacter Pylori Infection and Clinical Features of Colorectal Adenoma[J].Journal of Medical Information,2022,35(23):102.[doi:10.3969/j.issn.1006-1959.2022.16.024]
[4]华启洋,吴同利,刘永艳,等.幽门螺杆菌在胃食管反流病发病中的作用[J].医学信息,2019,32(20):103.[doi:10.3969/j.issn.1006-1959.2019.20.029]
　HUA Qi-yang,WU Tong-li,LIU Yong-yan,et al.The Role of Helicobacter Pylori in the Pathogenesis of Gastroesophageal Reflux Disease[J].Journal of Medical Information,2019,32(23):103.[doi:10.3969/j.issn.1006-1959.2019.20.029]
[5]陶源,徐俊林,张艳,等.上消化道黏膜病变病理诊断结果分析[J].医学信息,2020,33(02):125.[doi:10.3969/j.issn.1006-1959.2020.02.036]
　TAO Yuan,XU Jun-lin,ZHANG Yan,et al.Analysis of Pathological Diagnosis for Upper Gastrointestinal Mucosal Lesions[J].Journal of Medical Information,2020,33(23):125.[doi:10.3969/j.issn.1006-1959.2020.02.036]
[6]周 政.胃息肉与幽门螺杆菌感染的关系[J].医学信息,2021,34(21):91.[doi:10.3969/j.issn.1006-1959.2021.21.023]
　ZHOU Zheng.Relationship Between Gastric Polyps and Helicobacter Pylori Infection[J].Journal of Medical Information,2021,34(23):91.[doi:10.3969/j.issn.1006-1959.2021.21.023]
[7]黄 飞.不同用药方案治疗幽门螺杆菌感染胃溃疡的效果比较[J].医学信息,2020,33(16):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
　HUANG Fei.Comparison of the Effects of Different Medication Regimens in the Treatment of Gastric Ulcer Infected by Helicobacter Pylori[J].Journal of Medical Information,2020,33(23):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
[8]王蓓蓓,白 梅.黄芪建中汤加减联合四联疗法对Hp阳性胃溃疡患者Hp清除率及复发率的影响[J].医学信息,2022,35(20):145.[doi:10.3969/j.issn.1006-1959.2022.20.040]
　WANG Bei-bei,BAI Mei.Effect of Huangqi Jianzhong Decoction Combined with Quadruple Therapy on Hp Clearance Rate and Recurrence Rate in Patients with Hp Positive Gastric Ulcer[J].Journal of Medical Information,2022,35(23):145.[doi:10.3969/j.issn.1006-1959.2022.20.040]
[9]张 静,张鸿博.中医药治疗幽门螺杆菌相关性胃溃疡研究[J].医学信息,2022,35(20):173.[doi:10.3969/j.issn.1006-1959.2022.20.048]
　ZHANG Jing,ZHANG Hong-bo.Study on Traditional Chinese Medicine Treatment of Helicobacter Pylori Associated Gastric Ulcer[J].Journal of Medical Information,2022,35(23):173.[doi:10.3969/j.issn.1006-1959.2022.20.048]
[10]张运林.铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性[J].医学信息,2020,33(24):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]
　ZHANG Yun-lin.The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer[J].Journal of Medical Information,2020,33(23):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]

更新日期/Last Update: 1900-01-01